MORGUARD LINCLUDEN GLOBAL INVESTMENTS Ltd decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 274,989 shares of the biopharmaceutical company’s stock after selling 27,103 shares during the period. Pfizer comprises approximately 1.0% of MORGUARD LINCLUDEN GLOBAL INVESTMENTS Ltd’s holdings, making the stock its 28th biggest holding. MORGUARD LINCLUDEN GLOBAL INVESTMENTS Ltd’s holdings in Pfizer were worth $7,843,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC boosted its position in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the last quarter. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Keb Asset Management LLC purchased a new stake in shares of Pfizer during the second quarter worth about $26,000. Field & Main Bank purchased a new stake in shares of Pfizer during the second quarter worth about $27,000. Finally, Global Trust Asset Management LLC lifted its stake in shares of Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.
Wall Street Analyst Weigh In
PFE has been the subject of a number of analyst reports. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Scotiabank lifted their price objective on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. HSBC upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Finally, Cantor Fitzgerald increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.72.
View Our Latest Stock Report on PFE
More Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: ELREXFIO delivered a Phase 3 win. Pfizer said the MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit in relapsed or refractory multiple myeloma. The result could support broader use of the drug and strengthen Pfizer’s oncology pipeline. Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint
- Positive Sentiment: The FDA expanded the approval of TALZENNA plus XTANDI for earlier-line treatment of metastatic prostate cancer in patients with HRR gene mutations. The broader indication may increase the products’ commercial opportunity and diversify revenue beyond COVID products. FDA expands Pfizer’s Talzenna plus Xtandi approval
- Positive Sentiment: Analyst sentiment remained supportive. Scotiabank and Jefferies issued Buy ratings, while previews suggested Pfizer could beat upcoming earnings expectations. Pfizer’s recent results also exceeded consensus estimates for both revenue and adjusted earnings. Pfizer gets a Buy from Scotiabank
- Neutral Sentiment: Investors are focused on the upcoming Q3 report. Strong sales from newer medicines and a relatively attractive valuation could help, but the earnings release will need to demonstrate that Pfizer can offset ongoing COVID-product declines and longer-term patent risks. Pfizer Stock Ahead of Q3 Earnings
- Negative Sentiment: ELREXFIO’s benefit came with safety concerns. Reports highlighted higher infection rates, while median progression-free survival had not yet been reached. These details may temper the market’s reaction to the otherwise positive trial results. Pfizer’s ELREXFIO meets Phase 3 endpoint
- Negative Sentiment: Valuation and business-transition risks remain. Pfizer’s COVID revenue is declining, major products face future patent expirations, and one valuation analysis placed fair value near the current trading range, limiting perceived upside.
Pfizer Stock Performance
Shares of Pfizer stock opened at $29.46 on Thursday. The firm has a market cap of $167.90 billion, a PE ratio of 38.76, a price-to-earnings-growth ratio of 2.04 and a beta of 0.32. The firm’s 50-day simple moving average is $28.46 and its 200-day simple moving average is $26.74. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $30.44.
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.8%. Pfizer’s dividend payout ratio is presently 226.32%.
Pfizer Profile
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Featured Articles
- Five stocks we like better than Pfizer
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
